SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-24-002453
Filing Date
2024-01-16
Accepted
2024-01-16 16:30:49
Documents
63
Period of Report
2023-10-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1390246
2 ex10-10.htm EX-10.10 1117
3 ex19.htm EX-19 74739
4 ex23-1.htm EX-23.1 4519
5 ex31-1.htm EX-31.1 18420
6 ex31-2.htm EX-31.2 16861
7 ex32-1.htm EX-32.1 7074
8 ex32-2.htm EX-32.2 7328
9 ex99-1.htm EX-99.1 23039
10 ex10-10_001.jpg GRAPHIC 331019
  Complete submission text file 0001493152-24-002453.txt   6746899

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE anix-20231031.xsd EX-101.SCH 31741
12 XBRL CALCULATION FILE anix-20231031_cal.xml EX-101.CAL 40289
13 XBRL DEFINITION FILE anix-20231031_def.xml EX-101.DEF 168755
14 XBRL LABEL FILE anix-20231031_lab.xml EX-101.LAB 325571
15 XBRL PRESENTATION FILE anix-20231031_pre.xml EX-101.PRE 255176
57 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1098639
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-K | Act: 34 | File No.: 001-37492 | Film No.: 24535563
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)